We scan new podcasts and send you the top 5 insights daily.
Because bispecific antibody regimens are administered over numerous cycles (8 to 12 cycles or more), normal B cells are continually suppressed and cannot recover. This induces severe, persistent hypogammaglobulinemia. All patients receiving B-cell bispecifics require acyclovir prophylaxis for shingles, PJP prophylaxis if receiving steroids, and regular IVIG replacement therapy to avoid chronic sinus and upper respiratory tract infections.
Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.
Indefinite treatment with bispecific antibodies is likely unnecessary and exposes DLBCL patients to risks like hypogammaglobulinemia and recurrent infections. A fixed duration of no more than one year is a reasonable approach, with a readiness to stop earlier for patients in a deep, sustained complete response, potentially guided by ctDNA.
The powerful Tec-Dara combination therapy initially showed a paradoxical drop in overall survival due to infections. Mandating IVIG prophylaxis completely negated this early risk, revealing the treatment's true, significant long-term survival advantage. This highlights that aggressive supportive care is critical for maximizing efficacy.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.
To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.
Three-year data for odronextumab, given until progression in follicular lymphoma, reveals a high rate of severe (Grade 3+) infections (45%), including fatal events. This highlights a critical safety concern with continuous dosing and strengthens the clinical argument for using fixed-duration bispecific regimens to mitigate long-term toxicity.
The tolerability of therapies like bispecific antibodies has significantly improved not from changing the drug, but from evolving supportive care. Implementing low-threshold protocols for interventions like tocilizumab (for CRS) and IVIG (for infections) has made these once-complex treatments much safer and more manageable.
To manage hypogammaglobulinemia from bispecific antibodies, clinicians are adopting a more proactive approach. Following the model from myeloma care, they are initiating IVIG therapy earlier to prevent infections, rather than waiting for recurrent infections to occur as was standard with rituximab.
Clinicians often worry that steroid premedication or mitigation blunts the cytotoxic efficacy of bispecific antibodies. Dr. Budde points out that once T cells or CAR-T cells are fully activated, they become remarkably resistant to the immunosuppressive effects of steroids in both laboratory models and clinical practice, validating the safe use of steroids for toxicity management without compromising anti-tumor activity.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.